CERO THERAPEUTICS HOLDINGS, INC. financial statements
Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data CERO THERAPEUTICS HOLDINGS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2023
FY2025
Research and development
5.29
General and administrative
2.84
2.39
Operating expenses
2.91
7.68
Operating income
-2.91
-7.68
Interest expense
-0.14
Interest income
2.84
0.49
Other non-operating income
0.39
Pre-tax income
-0.07
-2.44
-19.9
Income tax
0.6
0.09
Net income
-0.67
-7.29
-19.9
EPS, basic
-1,249.00
EPS, diluted
-1,249.00
Shares, basic (weighted)
0.01
Shares, diluted (weighted)
0.01
Dividend per share
10.37
Balance sheet
FY2022
FY2023
FY2025
Cash and equivalents
0.48
0.1
1.66
Other current assets
0.23
0.37
1.07
Total current assets
42.4
1.97
2.73
Property, plant and equipment
0.97
0.25
Lease right-of-use assets
2.19
0.66
Total assets
42.4
5.13
3.64
Accounts payable
1.65
1.67
7.58
Accrued liabilities
0.14
0.36
Total current liabilities
30.7
3.51
9.09
Lease liabilities
1.58
Total liabilities
39.9
5.08
9.09
Paid-in capital
0
1.03
78.1
Retained earnings
-11
-43.1
-90.8
Shareholders' equity
-11
-42.1
-5.45
Total equity
-11
-42.1
-5.45
Total liabilities and equity
42.4
5.13
3.64
Shares outstanding
0.01
Cash flow statement
FY2022
FY2023
FY2025
Net income
-0.67
-7.29
19.9
Stock-based compensation
0.1
1.1
Deferred income tax
0
Change in payables
1.64
1.88
Cash from operations
-1.09
-1.52
-16.1
Purchases of investments
-179
Cash from investing
181
-7.94
Stock issued
0
Share buybacks
-139
-33.5
Dividends paid
-0.13
Cash from financing
-139
-32.6
Net change in cash
41
-42
Income taxes paid
0.67
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.00 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-858.5%
Net income / average total assets.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.05x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.03x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Book value per share
-$0.72
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-5,993.0%
Net income / market cap (the inverse of P/E).
Was CERO THERAPEUTICS HOLDINGS, INC. profitable in fiscal 2025?
No. It reported a net loss of $19.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.